Curespec

29/10/2026

🇨🇳 Another exciting milestone for Curespec in China!
On October 23, Nephrospec™ was officially introduced for clinical use at Boao Super Hospital in Hainan, China.
The launch event, organized by our Chinese partner, Guorun International Medical and Health Industry Group, marks another important step in expanding access to our non-invasive technology for patients with chronic kidney disease (CKD) and hypertension.
Our Clinical Affairs Manager, Dr. rivka fanta, joined the event and presented Nephrospec's technology and the progress of our clinical research.
A big thank you to our partners at Guorun and the Boao Super Hospital team for making this milestone possible.
We look forward to continuing our journey in China! 🇨🇳

hashtag hashtag hashtag hashtag hashtag hashtag

14/10/2026

Curespec & NephroNet Join Forces to Advance U.S. Clinical Development

Dear Friends and Partners,

We wanted you to be among the first to hear about an important milestone for Curespec.

Curespec and NephroRegenesis have signed a strategic collaboration agreement aimed at advancing Nephrospec™ through its next stages of clinical development in the U.S.

The framework includes a $1 million investment in Curespec associated with the pilot-stage collaboration and establishes the foundation for the planned pivotal clinical program in the U.S., with Curespec expected to serve as Sponsor and lead the regulatory dialogue with the FDA.

For us, this is much more than another collaboration. It represents an important step forward in our U.S. strategy and comes alongside Curespec’s continued clinical and commercial expansion in international markets.

We are sharing this update directly with our investors, partners, and selected contacts before communicating it more broadly.

For those who have been following Curespec and considering an investment, this may be an important time to reconnect with us. As the company enters its next stage of clinical and commercial development, we are currently holding discussions with potential investors regarding participation in

Curespec’s current investment round.

If you would like to explore the opportunity before the company moves into its next phase, please contact me directly.

Best regards,

The Curespec Team

30/09/2026

Another important step forward for Curespec in Europe. 🇩🇪

Today, our CEO, Rotem Kaynan, and Dr. rivka fanta from our Clinical Affairs team completed the Study Initiation Visit (SIV) for our upcoming clinical study at Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin.

The double-blind, randomized controlled trial will be led by Prof. Markus van der Giet and will evaluate Nephrospec™ in patients with hypertension and chronic kidney disease.

Launching an RCT at Charité marks an important milestone in Curespec’s clinical journey and in our continued efforts to build robust clinical evidence for our non-invasive, kidney-targeted acoustic therapy.

A big thank you to Prof. van der Giet, Anna-Lisa Meinke and the entire Charité - Universitätsmedizin Berlin team for the collaboration and preparation that made this possible.

And a special thank you to Rotem and Rivka for leading Curespec’s efforts on the ground in Berlin.

Another step forward in building the clinical evidence behind NephroSpec™.

22/09/2026

🇧🇷 **Nephrospec™ arrives in Brazil**

We are pleased to mark another important step in Curespec’s international expansion.

This week, together with our local partner **DEALERMED**, we are introducing Nephrospec™ to the Brazilian nephrology community at the **Brazilian Congress of Nephrology in Belo Horizonte**.

Nephrospec delivers non-invasive, kidney-targeted Electro-Hydraulic Acoustic Therapy (eHAT), supporting Curespec’s ongoing work in chronic kidney disease and hypertension.

Brazil represents an important market for expanding physician awareness, building local clinical engagement, and bringing innovative renal care to more patients.

We look forward to developing our presence in Brazil together with DEALERMED and the local nephrology community.

10/09/2026

Curespec at UAA 2026 in Manila 🇵🇭

We were pleased to take part in the 23rd Urological Association of Asia (UAA) Congress, bringing together leading physicians, researchers, and healthcare professionals from across Asia and beyond.

For Curespec, being in the Philippines is especially meaningful as we continue to expand our clinical and commercial activities in the region and build awareness around Nephrospec™ and our non-invasive, kidney-targeted acoustic therapy.

The congress was a valuable opportunity to meet with physicians and partners, exchange perspectives on kidney health and innovation, and explore new opportunities for collaboration across Asia.

Thank you to everyone we met in Manila - we look forward to continuing the conversations.

07/09/2026

We’re pleased to share another important step in Curespec’s expansion in China.

Curespec has signed an expanded distribution agreement with Guorun International Medical and Health Industry Group, extending our collaboration from Lecheng, Hainan, to the Greater Bay Area (GBA).

This builds on the work already underway in China and creates new opportunities to expand access to Nephrospec™ across one of the country’s most important healthcare regions.

Beyond the commercial opportunity, broader use of Nephrospec may also enable us to build valuable real-world clinical experience and data, complementing our ongoing clinical activities and supporting continued physician engagement with the technology.

We’re looking forward to the next stage of our collaboration with the Guorun team and to continuing to grow Curespec’s presence in China.

Curespec

02/09/2026

We came. We pitched. We connected. 🚀
Yesterday, Curespec took the stage at Elevator Pitch Night to present Nephrospec™ and our vision for a new, non-invasive approach to hypertension through kidney-targeted therapy.
A great evening of innovation, meaningful conversations, and new connections with investors, entrepreneurs, and leaders from across the Israeli ecosystem.
A big thank you to Doron Koren and the Entrepreneurs Channel team for bringing us together, to Golden Emu Ventures for supporting the evening, and to The Stitch for hosting us.
Proud to see Curespec on stage - and even more excited about the conversations that followed.
On to the next milestone. 🚀

25/08/2026

Curespec keeps moving forward - and it’s especially exciting when our patients feel the difference. 💙
Our non-invasive treatment focuses on the strong connection between the kidneys and blood pressure, with encouraging results that continue to motivate us.
While we work toward making the treatment more widely accessible, private treatments are already available.
Meet Yossi, one of our happy patients, sharing his personal experience after completing the treatment. 🎥

More information about the treatment in the comments 👇

09/07/2026

We’re hiring! 🚀
Curespec is looking for a Global Sales Manager to join our growing international team.
If you have proven MedTech / Medical Device sales experience, a strong background in managing international distributors, and you're excited to help bring innovative technology to patients worldwide, we’d love to hear from you.

Join us and be part of the global expansion of a breakthrough technology for the treatment of chronic kidney disease and hypertension.
👉 All the details & apply here:

Lowering Blood Pressure Curing the Kidneys ~ Lowering Blood Pressure Curing the Kidneys ~ Join the Curespec Team Curespec is transforming the treatment of chronic kidney disease and hypertension—conditions affecting over 700 million people worldwide.Our proprietary Electro-Hydraulic Acoustic Thera...

18/06/2026

Another Milestone in Panama!
We are proud to announce the first treatment performed with the second device installed in Panama, marking another important step in expanding access to advanced care across the country.
This milestone demonstrates the growing adoption of our technology and the confidence that healthcare professionals continue to place in our solutions. Seeing a second system become operational and begin treating patients is a strong indicator of the impact this technology can have on clinical practice and patient outcomes.
With additional treatments already scheduled, we look forward to supporting more physicians and helping more patients benefit from innovative, minimally invasive care.
The momentum in Panama continues to grow. 🚀